Archives: Speakers

Charity Roddy serves as the Director of Patient Engagement for Therapeutics and Oncology at Moderna. In this capacity, she leads patient engagement initiatives, education, and recruitment efforts across oncology and rare disease programs. With over 15 years of diverse experience in the pharmaceutical industry, Charity has held various roles spanning the entire drug development lifecycle. She is deeply committed to enhancing the patient experience in clinical trials and advancing innovative approaches to patient engagement.

Eric Harvey is the Senior Director of Biometrics and Data Science at MMS. He has over 20 years of experience in pharmaceutical research, spanning pre-clinical through phase IV clinical trials, device and diagnostic studies. Prior to MMS, he led biostatistics, programming, data management, data science and information technology groups at various CROs. He also led a clinical research department at a large hospital system. Eric is a problem solver at heart whose focus is to identify data driven opportunities to increase efficiency and improve quality.

Kevin P Killeen, PhD is the Chief Scientific Officer at Matrivax Research & Development Corp.  Dr. Killeen has extensive training in the fields of molecular biology, microbiology, protein chemistry, immunology, and vaccinology.  His undergraduate BS degree is from Stonehill College (biology and chemistry), Ph. D from University of Rhode Island (microbiology), and post-doctoral fellowship at Harvard Medical School (molecular genetics and protein toxin chemistry).  Dr Killeen has more than 30 years of experience in the field of biotechnology at IDEXX Corp., VRI/AVANT-Celldex Inc, and Matrivax Corp.  He has published more than 30 vaccine manuscripts, authored four chapters, written several science reviews, is an inventor on more than ten patent/applications, and served for 12 years as a member of the URI Dean’s Advisory Council.  Dr. Killeen was the principal investigator (PI) on vaccine related grants and contracts exceeding $11 MM and coordinated greater than $13 MM in funding from the Bill & Melinda Gates Foundation.  Career highlights include the commercialization of two diagnostic tests, directing nine (9) vaccine candidates (live-attenuated/oral and subunit/injectable) into Phase 1 and 2 clinical trials, and guiding the clinical development of CholeraGarde^®, an oral, single-dose cholera vaccine towards a Phase 3 clinical trial and out-licensing.  Moreover, while at VRI, Dr Killeen identified and performed scientific due diligence on rotavirus vaccine candidate 89-12, advanced through Phase 2b studies and ultimately out-licensed to GSK and commercialized as Rotarix^®, a >$1 billion ‘blockbuster’ vaccine.

Ajay Sadhwani is an executive Life Science Professional with over 25 years of clinical research experience. Proven leader of cross functional teams and people management of large and small functional groups with a track record of successfully leading teams and motivating individuals to perform at their highest level.